Literature DB >> 25270193

Neural stem cell-based intraocular administration of ciliary neurotrophic factor attenuates the loss of axotomized ganglion cells in adult mice.

Kai Flachsbarth1, Katharina Kruszewski1, Gila Jung1, Wanda Jankowiak1, Kristoffer Riecken2, Lars Wagenfeld1, Gisbert Richard1, Boris Fehse2, Udo Bartsch1.   

Abstract

PURPOSE: To analyze the neuroprotective effect of intravitreally grafted neural stem (NS) cells genetically modified to secrete ciliary neurotrophic factor (CNTF) on intraorbitally lesioned retinal ganglion cells (RGCs) in adult mice.
METHODS: Adherently cultivated NS cells were genetically modified to express a secretable variant of mouse CNTF together with the fluorescent reporter protein Venus. Clonal CNTF-secreting NS cell lines were established using fluorescence activated cell sorting, and intravitreally grafted into adult mice 1 day after an intraorbital crush of the optic nerve. Brn-3a-positive RGCs were counted in flat-mounted retinas at different postlesion intervals to evaluate the neuroprotective effect of the CNTF-secreting NS cells on the axotomized RGCs. Anterograde axonal tracing experiments were performed to analyze the regrowth of the injured RGC axons in CNTF-treated retinas.
RESULTS: Intravitreally grafted NS cells preferentially differentiated into astrocytes that survived in the host eyes, stably expressed CNTF, and significantly attenuated the loss of the axotomized RGCs over a period of at least 4 months, the latest postlesion time point analyzed. Depending on the postlesion interval analyzed, the number of RGCs in eyes with grafted CNTF-secreting NS cells was 2.8-fold to 6.4-fold higher than in eyes with grafted control NS cells. The CNTF-secreting NS cells additionally induced long-distance regrowth of the lesioned RGC axons.
CONCLUSIONS: Genetically modified clonal NS cell lines may serve as a useful tool for preclinical studies aimed at evaluating the therapeutic potential of a sustained cell-based intravitreal administration of neuroprotective factors in mouse models of glaucoma. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  axonal regeneration; ciliary neurotrophic factor; glaucoma; intraocular stem cell transplantation; lentiviral vector; neural stem cells; neuroprotection; optic nerve lesion; retinal ganglion cell

Mesh:

Substances:

Year:  2014        PMID: 25270193     DOI: 10.1167/iovs.14-15266

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  23 in total

1.  Injectable Neurotrophic Factor Delivery System Supporting Retinal Ganglion Cell Survival and Regeneration Following Optic Nerve Crush.

Authors:  Melissa R Laughter; James R Bardill; David A Ammar; Brisa Pena; David J Calkins; Daewon Park
Journal:  ACS Biomater Sci Eng       Date:  2018-07-23

2.  Molecular Biomarkers for Glaucoma.

Authors:  Gala Beykin; Jeffrey L Goldberg
Journal:  Curr Ophthalmol Rep       Date:  2019-07-23

3.  Chemokine CCL5 promotes robust optic nerve regeneration and mediates many of the effects of CNTF gene therapy.

Authors:  Lili Xie; Yuqin Yin; Larry Benowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2021-03-02       Impact factor: 11.205

Review 4.  Gene transfer to the outflow tract.

Authors:  Yalong Dang; Ralitsa Loewen; Hardik A Parikh; Pritha Roy; Nils A Loewen
Journal:  Exp Eye Res       Date:  2016-04-27       Impact factor: 3.467

Review 5.  Inherited eye-related disorders due to mitochondrial dysfunction.

Authors:  Patrick Yu-Wai-Man; Nancy J Newman
Journal:  Hum Mol Genet       Date:  2017-08-01       Impact factor: 6.150

6.  Sustained Neural Stem Cell-Based Intraocular Delivery of CNTF Attenuates Photoreceptor Loss in the nclf Mouse Model of Neuronal Ceroid Lipofuscinosis.

Authors:  Wanda Jankowiak; Katharina Kruszewski; Kai Flachsbarth; Christos Skevas; Gisbert Richard; Klaus Rüther; Thomas Braulke; Udo Bartsch
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

Review 7.  Stem cell treatment of degenerative eye disease.

Authors:  Ben Mead; Martin Berry; Ann Logan; Robert A H Scott; Wendy Leadbeater; Ben A Scheven
Journal:  Stem Cell Res       Date:  2015-02-24       Impact factor: 2.020

Review 8.  Glaucoma -state of the art and perspectives on treatment.

Authors:  Anna Wójcik-Gryciuk; Małgorzata Skup; Wioletta J Waleszczyk
Journal:  Restor Neurol Neurosci       Date:  2015       Impact factor: 2.406

9.  CNTF Attenuates Vasoproliferative Changes Through Upregulation of SOCS3 in a Mouse-Model of Oxygen-Induced Retinopathy.

Authors:  Felicitas Bucher; Johanna M Walz; Anima Bühler; Edith Aguilar; Clemens Lange; Sophia Diaz-Aguilar; Gottfried Martin; Günther Schlunck; Hansjürgen Agostini; Martin Friedlander; Andreas Stahl
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-08-01       Impact factor: 4.799

Review 10.  Discovery and clinical translation of novel glaucoma biomarkers.

Authors:  Gala Beykin; Anthony M Norcia; Vivek J Srinivasan; Alfredo Dubra; Jeffrey L Goldberg
Journal:  Prog Retin Eye Res       Date:  2020-07-10       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.